Collegium Pharmaceutical, Inc. (COLL)
NASDAQ: COLL · Real-Time Price · USD
30.90
+0.55 (1.81%)
At close: Jul 7, 2025, 4:00 PM
32.49
+1.59 (5.15%)
After-hours: Jul 7, 2025, 5:35 PM EDT
Collegium Pharmaceutical Stock Forecast
Stock Price Forecast
The 4 analysts that cover Collegium Pharmaceutical stock have a consensus rating of "Strong Buy" and an average price target of $43.75, which forecasts a 41.59% increase in the stock price over the next year. The lowest target is $37 and the highest is $50.
Price Target: $43.75 (+41.59%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 9, 2025.
Analyst Ratings
The average analyst rating for Collegium Pharmaceutical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
---|---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Piper Sandler | Piper Sandler | Hold Reiterates $36 → $37 | Hold | Reiterates | $36 → $37 | +19.74% | May 9, 2025 |
Needham | Needham | Strong Buy Reiterates $46 | Strong Buy | Reiterates | $46 | +48.87% | Apr 9, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +61.81% | Mar 24, 2025 |
Piper Sandler | Piper Sandler | Hold Maintains $37 → $36 | Hold | Maintains | $37 → $36 | +16.50% | Feb 4, 2025 |
Needham | Needham | Hold → Strong Buy Upgrades $46 | Hold → Strong Buy | Upgrades | $46 | +48.87% | Jan 10, 2025 |
Financial Forecast
Revenue This Year
757.96M
from 631.45M
Increased by 20.04%
Revenue Next Year
788.14M
from 757.96M
Increased by 3.98%
EPS This Year
7.97
from 1.86
Increased by 329.42%
EPS Next Year
8.09
from 7.97
Increased by 1.48%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 786.7M | 840.9M | 871.4M | ||
Avg | 758.0M | 788.1M | 736.2M | ||
Low | 722.1M | 732.4M | 576.7M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 24.6% | 10.9% | 10.6% | ||
Avg | 20.0% | 4.0% | -6.6% | ||
Low | 14.4% | -3.4% | -26.8% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 11.13 | 11.20 | 10.50 | ||
Avg | 7.97 | 8.09 | 7.60 | ||
Low | 6.62 | 6.22 | 3.68 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 499.2% | 40.5% | 29.8% | ||
Avg | 329.4% | 1.5% | -6.1% | ||
Low | 256.8% | -21.9% | -54.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.